Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for UC in October 2023 based on the LUCENT-1 and LUCENT-2 trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the omvoh vs entyvio ulcerative colitis comparison.
IL-23 p19 vs Gut-Selective Mechanism
Omvoh (mirikizumab) binds the p19 subunit of interleukin-23, selectively blocking the Th17-driving cytokine that fuels UC inflammation. Its immune effects are systemic but narrowly focused on IL-23. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed colonic tissue, Entyvio quiets UC inflammation without meaningfully suppressing the immune system elsewhere. The mirikizumab vs vedolizumab UC distinction shapes how each drug performs in different patient populations and their long-term safety profiles.
UC Efficacy Data
Omvoh's UC efficacy rests on LUCENT-1 (induction) and LUCENT-2 (maintenance), which showed clinical remission rates of 24.2% on Omvoh versus 13.3% on placebo at week 12 and durable benefit through week 40 maintenance. Entyvio's UC efficacy was established in GEMINI-1 and confirmed in VARSITY, where vedolizumab was directly compared with adalimumab in a head-to-head trial. VARSITY showed Entyvio superior to Humira on clinical remission at 52 weeks (31.3% vs 22.5%), establishing vedolizumab as a strong first-line UC biologic. No head-to-head trial has directly compared Omvoh with Entyvio in UC. Indirect comparisons suggest similar clinical remission rates, with Omvoh offering distinctive bowel urgency data.
Onset of Action
Omvoh produces clinically meaningful response in UC by week 12, based on LUCENT. Entyvio's onset is slower, with meaningful response often not evident until week 10 to 14 and continued improvement through week 26. For UC patients with active symptoms who cannot tolerate a long ramp-up, Omvoh's slightly faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.
Bowel Urgency Outcomes
LUCENT captured bowel urgency improvement using validated urgency numerical rating scales, showing significant improvement at both induction and maintenance endpoints. This is a patient-reported outcome often undertreated in UC and a distinctive feature of Omvoh's data package. Entyvio's UC program did not evaluate urgency with the same rigor, though real-world data supports general symptom improvement on vedolizumab. For UC patients whose primary quality-of-life concern is urgency, Omvoh's outcome profile is distinctive in a way that may inform the choice.
Safety and Infection Risk
Both drugs have favorable safety profiles relative to anti-TNFs. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. Omvoh's UC safety data from LUCENT has been favorable, consistent with other IL-23 p19 biologics. For omvoh vs entyvio UC effectiveness and safety, both drugs are attractive to patients concerned about long-term infection risk on anti-TNFs.
Administration and Dosing
Omvoh uses IV induction at 300 mg every 4 weeks for three doses (weeks 0, 4, and 8), followed by subcutaneous maintenance at 200 mg every 4 weeks, per Lilly's Omvoh prescribing information. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. For UC patients comparing long-term dosing frequency, Entyvio's every-8-week IV maintenance is less frequent than Omvoh's every-4-week SC maintenance, while SC conversion on Entyvio moves to every-2-week injections. Choice often comes down to IV vs SC preference and infusion center access.
Anti-TNF Experienced Patients
For UC patients who have already failed an anti-TNF, both drugs have demonstrated efficacy. LUCENT-1 included biologic-experienced UC patients and showed meaningful response rates on Omvoh. Entyvio also has anti-TNF experienced data, with real-world cohorts showing comparable response rates in this population to other non-TNF options. For patients who have cycled through one anti-TNF and are choosing between Omvoh and Entyvio, trial data supports both drugs as reasonable second-line options. Your GI will weigh prior biologic exposure pattern, current disease severity, and comorbidities when making the recommendation.
Choosing With Your GI
For a UC patient deciding between Omvoh and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Omvoh tends to win on speed of onset, clinical remission rates at week 12, and distinctive bowel urgency outcomes from LUCENT. Entyvio tends to win on the narrowest systemic safety footprint, a head-to-head trial (VARSITY) establishing its superiority over Humira in UC, and less frequent IV maintenance. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction (week 12 for Omvoh, week 14 for Entyvio), what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency episodes, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.